UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 9, 2015
AMARANTUS BIOSCIENCE HOLDINGS, INC.
(Exact name of registrant as specified in
its charter)
Nevada |
000-55016 |
26-0690857 |
(State or other jurisdiction of
incorporation or organization) |
(Commission File Number) |
IRS Employer
Identification No.) |
655 Montgomery Street, Suite 900
San Francisco, CA |
94111 |
(Address of Principal Executive Offices) |
(Zip Code) |
(408) 737-2734
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written
communications pursuant to Rule 425 under the Securities Act |
| ¨ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act |
| ¨ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
On June
9, 2015, Amarantus Bioscience Holdings, Inc. (the “Company”) issued a press release announcing two late-breaking abstracts
on the LymPro Test® have been accepted
for presentation at the Alzheimer’s Association International Conference®
(AAIC) being held July 18-23, 2015, in Washington,
DC. Amarantus Diagnostics, Inc. is a Silver Sponsor of the 2015 AAIC. Amarantus Diagnostics is a wholly-owned subsidiary of Amarantus
Bioscience Holdings (OTCQB: AMBS).
A copy of the Company’s press release
is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
Exhibit No. |
|
Description |
|
|
|
|
|
|
99.1
|
|
Amarantus Bioscience Holdings, Inc. Press Release, dated June
9, 2015.
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
|
|
|
AMARANTUS BIOSCIENCE HOLDINGS, INC. |
|
|
|
|
|
|
|
|
|
|
|
|
Date: June 9, 2015 |
|
By: |
/s/ Gerald E. Commissiong |
|
|
|
|
|
Name: Gerald E. Commissiong |
|
|
|
|
|
Title: Chief Executive Officer |
|
|
|
|
|
|
|
|
|
|
Exhibit 99.1
Amarantus Diagnostics Announces Acceptance
of Two Late-Breaking
Abstracts on LymPro Test® Data at the 2015 Alzheimer’s Association
International
Conference®
-Amarantus Diagnostics is a Silver Sponsor
of AAIC-
SAN FRANCISCO, CA, and GENEVA, SWITZERLAND
– June 9, 2015 - Amarantus Diagnostics, a neurology-focused diagnostics company developing diagnostic tests for Multiple
Sclerosis and Alzheimer's disease, announced two late-breaking abstracts on the LymPro Test® have been accepted
for presentation at the Alzheimer’s Association International Conference®
(AAIC) being held July 18-23, 2015, in Washington, DC. Amarantus Diagnostics, Inc. is a Silver Sponsor of the 2015
AAIC. Amarantus Diagnostics is a wholly-owned subsidiary of Amarantus Bioscience Holdings (OTCQB: AMBS).
Amarantus Diagnostics will present data
from two studies on its LymPro blood-based diagnostic assay for Alzheimer's disease (AD) during AAIC poster sessions in abstracts
entitled:
“The LymPro Test®:
A Biomarker for Alzheimer’s Disease Using Blood Samples from Clinically Diagnosed Alzheimer’s Disease and Cognitively
Intact Subjects.”
“The LymPro Test®:
A Fit for Purpose Validation of a Flow Cytometric Assay to Assess Lymphocyte Proliferation in Peripheral Blood Lymphocytes in Alzheimer’s
Disease.”
The LymPro Test measures lymphocyte proliferation
in response to a mitogenic stimulus and quantifies the extent to which lymphocytes have entered the cell division cycle. Cell cycle
dysregulation in neurons is a key pathology in AD, that results in neuronal death and cognitive decline. In the LymPro Test, lymphocyte
measurements are used as a surrogate for this neuronal cell dysfunction.
About AAIC
The Alzheimer’s
Association International Conference® (AAIC) is the world’s
largest forum for the dementia research community. International investigators, clinicians and care providers gather annually
to share the latest study results, theories and discoveries to bring the world closer to breakthroughs in dementia science. As
part of the Alzheimer’s Association’s research program, AAIC serves as a catalyst for generating new knowledge about
dementia and fostering a vital, collegial research community.
About Alzheimer's Disease
According to the Alzheimer's Association,
it is estimated that over 5.4 million people in the United States suffer from Alzheimer's disease. Over 500,000 patients are diagnosed
annually, with nearly one-in-eight older Americans affected by the disease. Alzheimer's disease is the third leading cause of death
in the United States. The cost of unpaid care in the United States is estimated at over $210 billion annually. Total payments for
care are estimated at over $200 billion annually, including $140 billion in cost to Medicare and Medicaid. Alzheimer's expenditures
in the United States are expected to exceed $1.2 trillion by 2050. There is no cure or effective treatment for Alzheimer's disease.
Worldwide, about 35.6 million individuals have the disease and, according to the World Health Organization, the number will double
every 20 years to 115.4 million people with Alzheimer's by 2050.
About LymPro Test®
The Lymphocyte Proliferation Test (LymPro
Test®) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes to withstand an exogenous
mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's
disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons. LymPro is unique
in the use of peripheral blood lymphocytes (PBLs) as a surrogate for neuronal cell function, suggesting a common immune-based relationship
between PBLs and neurons in the brain.
About Amarantus BioScience Holdings,
Inc.
Amarantus BioScience Holdings (AMBS) is
a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, psychiatry, ophthalmology
and regenerative medicine. AMBS’ Therapeutics division has development rights to eltoprazine, a Phase 2b ready small molecule
indicated for Parkinson's disease levodopa-induced dyskinesia, adult ADHD and Alzheimer’s aggression, and owns the intellectual
property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is developing
MANF-based products as treatments for brain and ophthalmic disorders. AMBS’ Diagnostics division owns the rights to MSPrecise®,
a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis
(RRMS) at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test®)
for Alzheimer's disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual
property for the diagnosis of Parkinson's disease (NuroPro). AMBS also owns the discovery of neurotrophic factors (PhenoGuard™)
that led to MANF’s discovery.
For further information please visit www.Amarantus.com,
or connect with the Company on Facebook, LinkedIn,
Twitter and Google+.
Forward-Looking Statements
Certain statements, other than purely historical
information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results,
and the assumptions upon which those statements are based, are forward-looking statements. These forward-looking statements generally
are identified by the words "believes," "project," "expects," "anticipates," "estimates,"
"intends," "strategy," "plan," "may," "will," "would," "will be,"
"will continue," "will likely result," and similar expressions. Forward-looking statements are based on current
expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from
the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently
uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include,
but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates,
competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating
forward-looking statements and undue reliance should not be placed on such statements.
Investor and Media Contact:
Jenene Thomas
Jenene Thomas Communications, LLC
Investor Relations and Corporate Communications
Advisor
T: (US) 908.938.1475
E: jenene@jenenethomascommunications.com
Source: Amarantus Bioscience Holdings,
Inc.
###
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Sep 2023 to Sep 2024